Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
Alder hopes soon to launch its migraine drug eptinezumab, and will nervously have been watching the first full quarter’s sales of three similarly acting drugs.
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
Sage Therapeutics will report the first pivotal data with its oral postpartum depression candidate, while Biohaven Pharma transfers its hopes to a faster-acting migraine…
Competition in the CGRP migraine space has left both Teva and Amgen willing to take hits on sales to hook new patients.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Biohaven might soon be going up against Allergan in the acute migraine space, but the company believes size will not be a barrier to its success.